Agent "angiotonik" and method for supporting therapy in diseases of cardiovascular system


FIELD: medicine, cardiology, chemical-pharmaceutical industry.

SUBSTANCE: invention relates to development of a complex from vegetable raw, vitamins, amino acids, trace elements and macroelements used in treatment of cardiovascular system diseases in carrying out the supporting therapy. Agent used in treatment of cardiovascular system in carrying out the supporting therapy contains as active components vitamins, bioflavonoids, trace elements, macroelements, extracts from medicinal plants, red grape polyphenol complex, broccoli concentrate, borage oil, L-cysteine, L-glutathione, D,L-methionine, and special supplements as cellulose, silicon dioxide, stearic acid, magnesium stearate and hydroxypropylcellulose, and this agent is made as a tablet formulation in the definite content of components per one tablet, in mg. Agent is designated in carrying out the supporting therapy in hypertensive disease of I-II degree, ischemic heart disease I-II of the functional class , neurocirculatory dystonia of different types. Agent is prescribed in the dose one tablet 1-2 times before eating or with food by course for one month. "AngioTonik" is agent able to provide body by all nutrient substances that are necessary for normal function of cardiovascular system.

EFFECT: valuable medicinal properties of agent.

5 cl, 5 tbl, 3 dwg

 

The invention relates to chemical-pharmaceutical industry, namely the creation of a complex of vegetable raw materials, vitamins, amino acids, micro - and macroelements for the treatment of diseases of the cardiovascular system.

It is known that cardiovascular diseases are among the most common diseases of mankind. Nervous, mental workload, stress, permanent environmental degradation leads to deterioration of the cardiovascular system.

There are certain General guidelines. To follow a diet with very low sugar content, to avoid margarine and any similar fats, there are at least three times per week of fatty fish, to use for cooking, flax and olive oil, to include in the diet of nuts and seeds rich in essential fatty acids, etc.

In addition, for the prevention of heart disease, you can take antioxidants, minerals, and herbal remedies (Supplements Dr. Atkins, M.: Ripollet, 2000, 378-384).

The disadvantages of the known means is either limited pharmacological orientation, or too large in terms of treatment and as a consequence weak therapeutic effect.

Object of the invention is the creation of a complex for use in cardiology practice, which D. who has the power to increase physical activity, to stabilize the pressure and the blood, improve ECG and reduce episodes of arrhythmia.

The proposed group of inventions combined to form a single inventive concept.

The proposed tool for maintenance therapy of diseases of the cardiovascular system, containing as active ingredients, vitamins, bioflavonoids, micro - and macro-elements, extracts of medicinal plants, a complex of polyphenols in red grape concentrate broccoli, borage seed oil, L-cysteine, L-glutathione, DL-methionine and targeted ingredients: cellulose, silicon dioxide, stearic acid, magnesium stearate, hypromellose, this tool is made in the form of tablets in the following ingredients per tablet, mg:

Beta carotene1980-2420 ME
Vitamin C (ascorbate)603,0-737,0
Bioflavonoids15,3 is 18.7
Vitamin E (mixed Tocopherols)90-110 ME
Vitamin B1(thiamine hydrochloride)0,675-0,825
Vitamin b2(Riboflavin)0,765-0,935
Vitamin b3(Niacin)15,3 is 18.7
Vitamin b6(pyridoxine hydrochloride)2,7-3,3
Poliev the I acid 119,7-146,3
Vitamin B12(cyanocobalamin)1.8-to 2.2 µg
D-Biotin90-110 μg
Vitamin b5(Pantothenic acid)of 6.3 to 7.7
Iodine (potassium iodide)45-55 mcg
Zinc (ascorbate)4,5-5,5 mg
Selenium (L-Selenomethionine)27-33 mcg
Cobalt (amino acid chelate)1.8-to 2.2 µg
Boron (citrate, aspartate)0,9-1,1
The complex of polyphenols from red grapes9,0-11,0
The extract of Ginkgo biloba (Ginkgo biloba)
- standardized to 24% found in Ginkgo,
6% terpene4,5-5,5
Bilberry extract (Vaccinium myrtillus)
- standardized to 25%4,5-5,5
L-cysteine29,7-36,3
Concentrate broccoli (Brassica canliflora)9,0-11,0
The extract of red cabbage (Brassica oleracea)9,0-11,0
L-Glutathione1,53-1,87
Borage seed oil (Borago officinalis) - 24% GLA29,7-36,3
Manganese (ascorbate)1,17-1,43
Chromium (ascorb is, picolinate)29,7-36,3 mcg
Molybdenum (ascorbate)40,5-49,5 mcg
Copper (citrate)0,9-1,1
Calcium (ascorbate)18,0-22,0
Phosphorus (dicalcium phosphate)the 10.8 and 13.2
Potassium (citrate, aspartate)18,0-22,0
DL-Methionine2,97-3,63
Magnesium (ascorbate)20,97-at 25.63
Cellulose81,0-99,0
Silicon dioxideof 5.4 and 6.6
Stearic acid19,8-24,2
Magnesium stearate21,6-26,4
Hydroxypropyl methylcellulose9,0-11,0

The tool may contain the active ingredients in one tablet, mg:

Beta carotene2200 ME
Vitamin C (ascorbate)670,0
Bioflavonoidsof 17.0
Vitamin E (mixed Tocopherols)100 ME
Vitamin B1(thiamine hydrochloride)0,75
Vitamin b2(Riboflavin)0,85
Vitamin b3(Niacin)of 17.0
Vitamin b6(pyridoxine hydrochloride)3,0
Folic acid133 mcg
Vitamin b12(cyanocobalamin)2 mcg
D-Biotin100 mcg
Vitamin b5(Pantothenic acid)7,0
Iodine (potassium iodide)50 mcg
Zinc (ascorbate)5,0
Selenium (L-Selenomethionine)30 mcg
Cobalt (amino acid chelate)2 mcg
Boron (citrate, aspartate)1,0
The complex of polyphenols from red grapes10,0
The extract of Ginkgo biloba (Ginkgo biloba)
- standardized to 24% found in Ginkgo,
6% terpene5,0
Bilberry extract (Vaccinium myrtillus)
- standardized to 25%5,0
L-cysteine33,0
Concentrate broccoli (Brassica canliflora)10,0
The extract of red cabbage (Brassica oleracea)10,0
L-Glutathione1,7
Borage seed oil (Borago officinalis) - 24% GLA33,0
Manganese (ascorbate)1,3
Chromium (ascorbate, pikal the NAT) 33 mcg
Molybdenum (ascorbate)45 mcg
Copper (citrate)1,0
Calcium (ascorbate)20.0
Phosphorus (dicalcium phosphate)to 12.0
Potassium (citrate, aspartate)20,0
DL-Methionine3,3
Magnesium (ascorbate)23,3
and special additives, mg:

Cellulose
90,0
Silicon dioxide6,0
Stearic acid22,0
Magnesium stearate24,0
Hydroxypropyl methylcellulose10,0

The above tool is intended for maintenance therapy of hypertension I-II degree, CHD FC I-II, neurocirculatory dystonia of different types.

Proposed method of maintenance therapy of diseases of the cardiovascular system, which consists in the fact that you accept the above means one tablet 1-2 times during or after a meal, taking one month.

The tool is called "Angiogenic".

The tool get in a known manner to obtain tablets, set in pharmacy practice.

Angiolini - a tool that can provide the body with all the nutrients, n is necessary for the normal functioning of the cardiovascular system.

Part of Angioedema is complex vitamins. Vitamins C, E and beta-carotene (provitamin a) are antioxidants and protect the body from free radicals. B vitamins support the nervous system, which is very important, as in the formation of heart disease the important role played by emotional stress. In addition, it was found that deficiency of vitamin b1and In6correlates with an increased risk of developing coronary artery disease, and the reduction of folic acid is associated with increased mortality from cardiovascular events.

Angiogenic contains macro - and micronutrients necessary for the heart, normalize blood vessels, maintaining normal metabolism in the body and many other functions.

The composition of the formula is borage oil, which is a rich source of polyunsaturated fatty acids, lowers cholesterol and improves rheological (liquid) properties of blood.

Part of Angioedema also includes extracts of medicinal plants, which improve the condition of the cardiovascular system. Ginkgo biloba and bilberry help to strengthen the walls of the arterial and venous vessels, resulting in improved circulation.

Extracts of red cabbage, broccoli and complex polyphenols from red grapes oblad who have high antioxidant activity and protect the body from free radicals.

The amino acid methionine and the Tripeptide glutathione help to reduce cholesterol levels, accelerate the breakdown of fats in the body, beneficial effects on the nervous system.

N-acetylcysteine stimulates the synthesis of endogenous glutathione, reduces blood levels of "bad" (atherogenic) LDL contributes to a more complete excretion of toxic products (salts, heavy metals and so on).

Specific interaction of vitamins, minerals and medicinal plants of Angioedema provides nutrition to the heart muscle and improves blood flow to all organs and tissues of the body.

The course of action and indications for use: recommended as a complex of vitamins, minerals and biologically active substances of plants to supply the physiological functions of the cardiovascular system.

How to use: take 1 tablet 1-2 times a day during meals.

Contraindications: individual intolerance to the components.

The tool was tested on volunteers.

The results of the clinical application of Angiogenic".

Study of the efficacy and tolerability of biologically active food supplements "Angiogenic" was conducted among adults in the Clinic of clinical nutrition, Institute of nutrition Russian Academy of medical Sciences (Moscow) and in adolescents in the Institute of nutrition at Krasgma on the basis of liricheskogo separation of somatic and mental health of children research Institute of medical problems of the North SB RAMS and the Department of clinical immunology Krasgma (Krasnoyarsk).

Study group:

Adults.

1. The main group of patients 20 patients (3 men and 17 women) with hypertension I-II century and coronary heart disease (I-II century aged 40 to 67 years (mean age 58.5 years)treated with biologically active food Supplement "Angiogenic".

2. A comparison group of 20 people (4 men and 16 women) with CHD and GB in age from 43 to 65 years (mean age of 58.3 years).

Diagnosis of diseases and their severity was based on clinical, ECG and Echocardiography.

The clinical picture of patients on admission to the hospital was fairly typical in the two groups. The symptoms of coronary artery disease and GB depended on the severity of these diseases.

Teenagers:

39 adolescents (22 boys and 17 girls) with vegetative dysfunction syndrome aged 14 to 17 years (mean age of 15.8 years). The survey was carried out before and after administration of biologically active food supplements "Angiogenic" for over 1 month.

Dosage and administration: adults and adolescents the drug is administered at a dose of 1 tablet 2 times a day within 1 hour after a meal within 1 month.

Methods.

Complex patients in the Clinic of medical nutrition included the study of the dynamics of objective signs of disease: blood pressure (BP), heart rate decrease in the s (HR), assessment of tolerability BAD.

Assessed biochemical parameters characterizing the state of lipid, carbohydrate, and protein metabolism. The content of VLDL cholesterol, LDL cholesterol, HDL cholesterol and magnitude of the coefficient of haemoglobin was determined by the calculation method.

Assessment of tolerance of BAD adults was conducted registration, polling method.

Estimated efficiency of BAA "Angiogenic" compared with standard diet-A1, used in patients with cardiovascular diseases.

Characteristic diets A1: Hyponatriemia atherogenic diet with reduced amounts of animal fats, refined carbohydrates, cholesterolaemia products and extractives. The protein content in the diet corresponds to the physiological norm, and includes products that contain lipotropic substances, polyunsaturated fatty acids, dietary fiber.

The results:

I. study of the efficiency of BAA "Angiogenic" in adults with GB and coronary heart disease.

It was noted positive dynamics of clinical indicators. The obtained data are presented in table 1.

As can be seen from this table 1, under the influence of diet in the majority of patients decreased or disappeared headache, weakness, fatigue, dyspnea on exertion, edema of the legs in the evening, the sense of disruption in the heart's work. One is to the percentage of patients have noted the positive dynamics of these indicators adding BAD, was slightly higher compared to the comparison group.

Positive dynamics on ECG were observed in 50% of patients of the main group and in 45% of patients in the comparison group and was manifested by normalization of rhythm (the disappearance of the sinus of the and bradycardia, isolated ventricular and supraventricular extrasystoles) a decrease in the severity of symptoms of coronary insufficiency (as judged on the basis of changes of interval S-T and the T wave).

Table 2 presents data on the dynamics of blood pressure and heart rate in patients receiving BAD "Angiogenic".

As can be seen from table 2, the decline in systolic blood pressure was observed in both groups and amounted to 21.0% in patients of the main group and 19.5% in the comparison group that was not statistically significant. However, the decrease in diastolic pressure up to 78 mm Hg(21, 4%) was observed in the group of BAD, whereas in the comparison group DBP decreased by 12.5% to 88,6 mm Hg, what is the upper limit of normal (see figure 1) heart rate during treatment had a small tendency to decrease in patients of both groups.

Analysis of the results of biochemical studies in the serum (see table 3) shows that the inclusion of SUPPLEMENTS in addition to the basal diet A1 contributed statistically significant (p<0,05) decrease the level of the I total and LDL cholesterol in the serum (19.0%, 25,6%, respectively). In the comparison group showed reliable changes in these parameters by 12.5% and 19.3%. The value of the coefficient for haemoglobin decreased in patients of the main group and comparison group. 18,3% and 13.5%, respectively. Comparative dynamics of these indicators are presented in chart 2. In relation to other biochemical indicators were not found.

Portability BAD was good. For the entire period of clinical trials has not been a single case of rejecting BAD, dyspeptic symptoms, allergic reactions and other side effects. After completion of clinical trials, all patients who took part in them, expressed a desire to continue taking proven SUPPLEMENTS at home.

II. Study of the efficiency of BAA "Angiogenic" in adolescents with neurocirculatory dystonia.

The positive clinical effect of application of Angioedema" in the correction of autonomic disorders observed in 36 (92,31%) children with neurocirculatory dystonia. In children receiving "Angiogenic", there was a General improvement of health, emotional status, they have significantly reduced the number of complaints, there is a tendency to normalization of the altered systolic and diastolic blood pressure (SBP and DBP). None of the children receiving drugs is at, not mentioned allergic reactions or dyspeptic disorders.

The drug favorably influenced indicators of cerebral hemodynamics: decreased manifestations of vascular amiodarone brain, impaired venous outflow, there was a trend toward normalization of quantitative indicators rogramme and the degree of interhemispheric asymmetry of cerebral blood flow.

Analysis of data from a study of the ANS functional state, showed that the positive effect of cardio-tonic manifested to a greater extent in children with sympathicotonic type of syndrome of vegetative dysfunction, as evidenced by the tendency to normalization of the original vegetative tonus (IWT) and the increase in the number of children with atonia in this group, a decrease in the frequency of occurrence and Hyper sympathicotonic gipergeometricheskoi (itself against non-adaptable) type reactions hemodynamics on the KOP. It was noted positive dynamics of quantitative indicators kardiointervalogrammy testifying to reduce the influence of the sympathetic division of the autonomic regulation of the cardiovascular system.

In the group of children with vagotomies option autonomic dysfunction positive effect of Angioedema", in contrast, was affected by the increase in sympathetic tone is on and reducing the effect of the parasympathetic division of the ANS, that was confirmed by normalization of IWT in the direction of atonia (37% of children), reducing the number of children with excessive vegetative reactivity (Hyper sympathicotonic), the increase in the frequency of sympathicotonia normal) autonomic reactivity, increasing the number of children with normal variant clinorotation and a decrease in the number of children with pathological reactions hemodynamics on the KOP (sympathetic-asthenic, astheno-sympathetic and gipergeometricheskoi)that testified to optimize the functioning of the ANS in progress clinorotation samples.

In General, the group noted the positive dynamics of lipid parameters. This was reflected in the reduction in the average level of cholesterol low-density lipoprotein (atherogenic fraction), the decrease in atherogenic index (3,249±0,165 to 2,500±0,155, p<0.001) and increased cholesterol high density lipoprotein (HDL-C), which is atherogenic fraction and helps prevent the development of atherosclerotic process and early development of coronary heart disease and myocardial infarction. Generalized data on the dynamics of lipid indices in adolescents with NDC presented in table 4 and figure 3.

The most significant positive changes in the lipid spectrum of blood serum was observed in the group of pupils who had sympathicotonic type of the vegetative nervous system they atherogenic changes in lipid spectrum was significantly decreased, whereas in children with vagotomies type SVD was observed less pronounced positive dynamics of lipid parameters.

Table 5 presents data on the dynamics of enzyme status in children depending on the type of dysfunction: a statistically significant increase in the activity of the enzyme G-6-FDG and NADP-GDH in children with vagotomies types of autonomic dysfunction and LDH in children with sympathicotonia orientation autonomic disorders. In the group of young statistically significant differences in the enzyme activity, determined before and after application of Angioedema", not received. At the same time, in the group of girls revealed a trend towards a statistically significant increase in the activity of NADP-IGD and the trend towards a statistically significant decrease in the content of the ABOVE-MDY.

The use of biologically active additives "Angiogenic" against hyponatriemia atherogenic diet in patients with coronary artery disease and GB I-II century has a beneficial effect on the clinical picture of these diseases.

The use of Angioedema" in adolescents with vascular dystonia vest is the duty to regulate the reduced severity of clinical sympotoms, the normalization of autonomic reactivity.

"Angiogenic" enhances the hypotensive effect of diet A1.

Under the influence of the inclusion of dietary SUPPLEMENTS in the diet in CHD patients and GB with hyperlipidemia and adolescents with sympatotonics type of dysfunction observed a more marked reduction in the level of atherogenic lipoprotein fractions in serum (total cholesterol, LDL cholesterol) and coefficient value for haemoglobin than patients in the comparison group.

"Angiogenic" well tolerated, does not cause allergic or other adverse reactions.

"Angiogenic" can be recommended for use as a dietary Supplement, improves the functional condition of cardiovascular system in patients with ischemic heart disease I-II FC, GB I-II century, neurocirculatory dystonia of different types.

1. Means for supporting the treatment of diseases of the cardiovascular system, characterized in that it contains as active ingredients, vitamins, bioflavonoids, micro - and macro-elements, extracts of medicinal plants, a complex of polyphenols in red grape concentrate broccoli, borage seed oil, L-cysteine, L-glutathione, DL-methionine and special additive cellulose, silicon dioxide, stearic acid, magnesium stearate, hypromellose, this tool is made in the form of tablets with the following contents ingredien the s per tablet, mg:

Beta carotene1980-2420 ME
Vitamin C (ascorbate)603,0-737,0
Bioflavonoids15,3 is 18.7
Vitamin E (mixed Tocopherols)90-110 ME
Vitamin B1(thiamine hydrochloride)0,675-0,825
Vitamin b2(Riboflavin)0,765-0,935
Vitamin b3(Niacin)15,3 is 18.7
Vitamin b6(pyridoxine hydrochloride)2,7-3,3
Folic acid119,7-146,3
Vitamin b12(cyanocobalamin)1.8-to 2.2 µg
D-Biotin90-110 μg
Vitamin B5(Pantothenic acid)of 6.3 to 7.7
Iodine (potassium iodide)45-55 mcg
Zinc (ascorbate)4,5-5,5
Selenium (L-Selenomethionine)27-33 mcg
Cobalt (amino acid chelate)1.8-to 2.2 µg
Boron (citrate, aspartate)0,9-1,1
The complex of polyphenols from red grapes9,0-11,0
The extract of Ginkgo biloba (Ginkgo bilobd) -
standardized what about the 24% found in Ginkgo,
6% terpene4,5-5,5
Bilberry extract (Vaccinium myrtillus) -
standardized to 25%4,5-5,5
L-cysteine29,7-36,3
Concentrate broccoli (Brassica canliflora)9,0-11,0
The extract of red cabbage (Brassica oleracea)9,0-11,0
L-glutathione1,53-1,87
Borage seed oil {Borago officinalis} - 24% GLA29,7-36,3
Manganese (ascorbate)1,17-1,43
Chromium (ascorbate, picolinate)29,7-36,3 mcg
Molybdenum (ascorbate)40,5-49,5 mcg
Copper (citrate)0,9-1,1
Calcium (ascorbate)18,0-22,0
Phosphorus (dicalcium phosphate)the 10.8 and 13.2
Potassium (citrate, aspartate)18,0-22,0
DL-methionine2,97-3,63
Magnesium (ascorbate)20,97-25,63
Cellulose81,0-99,0
Silicon dioxideof 5.4 and 6.6
Stearic acid19,8-24,2
Magnesium stearate21,6-26,4
Hydroxypropyl methyl cellulose9,0-11,0

2 the Tool according to claim 1, where the content of the active ingredients in one pill is mg:

Beta carotene2200 ME
Vitamin C (ascorbate)670,0
Bioflavonoidsof 17.0
Vitamin E (mixed Tocopherols)100 ME
Vitamin B1(thiamine hydrochloride)0,75
Vitamin b2(Riboflavin)0,85
Vitamin b3(Niacin)of 17.0
Vitamin b6(pyridoxine hydrochloride)3,0
Folic acid133 mcg
Vitamin b12(cyanocobalamin)2 mcg
D-Biotin100 mcg
Vitamin B5(Pantothenic acid)7,0
Iodine (potassium iodide)50 mcg
Zinc (ascorbate)5,0
Selenium (L-Selenomethionine)30 mcg
Cobalt (amino acid chelate)2 mcg
Boron (citrate, aspartate)1,0
The complex of polyphenols from red grapes10,0
The extract of Ginkgo biloba (Ginkgo biloba) -
standardized to 24% found in Ginkgo,
6% terpene5,0
Bilberry extract (Vaccinium myrtillus) -
standardized to 25%5,0
L-cysteine33,0
Concentrate broccoli {Brassica canliflora}10,0
The extract of red cabbage {Brassica oleracea}10,0
L-glutathione1,7
Borage seed oil (Borago qfficinalis) - 24% GLA33,0
Manganese (ascorbate)1,3
Chromium (ascorbate, picolinate)33 mcg
Molybdenum (ascorbate)45 mcg
Copper (citrate)1,0
Calcium (ascorbate)20,0
Phosphorus (dicalcium phosphate)to 12.0
Potassium (citrate, aspartate)20,0
DL-methionine3,3
Magnesium (ascorbate)23,33

3. The tool according to claim 1, where the content of the target supplements in one pill is mg:

Cellulose90,0
Silicon dioxide6,0
Stearic acid22,0/td>
Magnesium stearate24,0
Hydroxypropyl methyl cellulose10,04

4. The tool according to claim 1 intended for maintenance therapy of hypertension I-II degree, CHD FC I-II, neurocirculatory dystonia of different types.

5. Way maintenance therapy of diseases of the cardiovascular system, characterized by the fact that accept the tool according to claim 1 one tablet 1-2 times during or after a meal, taking one month.



 

Same patents:

FIELD: medicine, therapy.

SUBSTANCE: method involves combination of complex of conventional therapy in treatment of bronchopulmonary pathology involving using broncholytic agents, mucolytic agents and inhalation corticosteroids with additional administration of "Kordafleks-retard" in the dose 20 mg, 2 times per 24 h by course for one year. Such realization of the method provides the effective treatment based on the potentiation effect of bronchodilating agents in combination with reducing frequency of adverse effect arising, in particular, tachycardia. Invention can be used in treatment of systemic and pulmonary arterial hypertension in patients with chronic obstructive bronchitis and bronchial asthma.

EFFECT: improved method of treatment.

1 ex

FIELD: medicine, cardiology, pharmacy.

SUBSTANCE: invention relates to medicaments, namely, to using 2-[1-(1,1-dioxothietanyl-3)-benzimidazolyl-2-tho]acetic acid potassium salt of the formula: as a substance enhancing resistance of cardiac muscle against ischemia. Invention provides the stable cardioprotective effect in myocardium ischemia as compared with prototype (preparation obsidan).

EFFECT: enhanced effectiveness and valuable medicinal properties of agent.

4 tbl, 2 ex

FIELD: medicine, cardiology, pharmacy.

SUBSTANCE: invention relates to an anti-arrhythmic medicament in combination with amiodarone that comprises thiotriazoline in the ratio to amiodarone = 1:2 by dry matter. Proposed medicament possesses the more expressed anti-arrhythmic effect as compared with prototype (preparation amiodarone).

EFFECT: enhanced and valuable medicinal property of agent.

2 cl, 4 tbl, 4 dwg, 2 ex

FIELD: medicine, pharmacy, chemical-pharmaceutical industry.

SUBSTANCE: invention relates to a method for preparing metoprolol homogenous microparticles that is carried out by treatment of in a fluidized layer. Microparticles have granulometric composition less 250 mcm and comprise at least 80 wt.-% of metoprolol. Metoprolol homogenous microparticles are used for preparing a medicament used in prophylaxis or treatment of cardiovascular disorder. Method is suitable, reproducible and rapid.

EFFECT: improved preparing method.

23 cl, 2 ex

FIELD: medicine.

SUBSTANCE: compound is represented by structural formula

or its pharmaceutically permissible salts, where R1 is the hydrogen atom (1), C1-8acyl(2), hydroxyl (3), halogen atom (5), C2-8acyl (3), C1-8-alcocsy (4), substituted with phenyl or C2-8acyl, substituted with NR2R3; R2R3 independently represent hydrogen atom (1) or C1-8acyl(2), X and Y each independently representing C (1), CH (2) or N (3). is (1) single or (2) double bond. is 5-7-member carbocyclic group or 5-7-member partially or fully saturated heterocyclic group defined in claim 1 of invention. A is one of A1 to A5 groups defined by claim 1 of the invention. The compounds show inhibiting properties relative to poly(ADP-ribose)polymerase are usable as prophylactic and/or curative drugs for treating ischemic diseases (in brain, spinal cord, heart, digestive tract, skeletal muscle, eye retina, e.t.c.), inflammatory diseases (intestinal inflammation, disseminated sclerosis, arthritis, e.t.c.), neurodegenerative disorders (extrapyramidal disorder, Alzheimer disease, muscle dystrophy, cerebrospinal canal stenosis in lumbar segment of the vertebral column, e.t.c.), diabetes, stroke, cerebral injury, hepatic insufficiency, hyperalgesia, e.t.c. The compounds are also of use in struggling against retroviruses (HIV and others), as sensitizing agents for treating cancer cases and immunodepressant agents.

EFFECT: enhanced effectiveness of treatment.

19 cl, 90 tbl

FIELD: medicine.

SUBSTANCE: preparation comprises Amlodipine taken in quantity corresponding to free base content from 6 mg to 10 mg and Benazepril/benazeprilate corresponding to Benazepril hydrochloride content not exceeding 40mg.

EFFECT: enhanced effectiveness of arterial blood pressure control.

28 cl

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to triheterocyclic compound of the formula (I): wherein X represents carbon atom; Y represents carbon or nitrogen atom; W represents carbon or nitrogen atom; U represents -CR2, and Z represents -CR2 or nitrogen atom; ring A represents (C5-C6)-cycloalkyl ring or 5-membered heterocyclic ring comprising one nitrogen, oxygen or sulfur atom; R1 represents alkyl, alkenyl, alkynyl, -NR4R5, -OR6 and others; R3 represents phenyl ring substituted with 1-3 substitutes or pyridyl or 1,3-dioxoindanyl ring substituted with 1-2 substitutes, and its pharmaceutically acceptable salts and pharmaceutical composition containing thereof as an active component. Also, invention relates to derivatives of pyrazolopyrimidine and derivatives of pyrrolopyrimidine. Compounds of the formula (I) show antagonistic activity with respect to corticotropin-releasing factor receptors. The compound can be used in treatment and/or prophylaxis of depression, anxiety state, disorders in food intake, post-traumatic stress, ulcerous disease, irritable bowel syndrome, Alzheimer's disease, abuse in drugs using or alcoholic syndrome dependence.

EFFECT: valuable medicinal properties of compounds and pharmaceutical agent.

7 cl, 1 dwg, 24 ex

FIELD: organic chemistry, medicine.

SUBSTANCE: invention relates to derivatives of benzopyrane of the formula (1)

or the formula (2) ,

wherein each R1 and R2 means independently of one another hydrogen atom; R3 means hydroxyl group; R4 means hydrogen atom; R5 means (C1-C6)-alkyl group substituted with (C6-C14)-aryl group wherein indicated (C1-C6)-group can be substituted optionally with hydroxyl, methyl group and indicated (C6-C14)-aryl group can be substitute optionally with 1-3 radicals R7 (wherein R7 represents halogen atom or amino-group) or linear (C5-C8)-alkyl group; R6 means (C1-C6)-alkyl group (wherein indicated alkyl group can be substituted optionally with hydroxyl or amino-group), halogen atom, nitro-group or -C(O)NH2 but excluding compound of the formula (1) wherein R means -NO2 at position 6; R5 means -CH2CH2Ph, and R1 and R2 mean methyl group, and compound of the formula (1) wherein R6 means bromine atom at position 6; R5 means benzyl and R1 and R2 mean methyl group, or their pharmaceutically acceptable salts, and a pharmaceutical preparation based on thereof. Proposed compounds are useful as anti-arrhythmic agents.

EFFECT: valuable medicinal properties of compounds and pharmaceutical composition.

8 cl, 7 tbl, 26 ex

FIELD: medicine, pharmaceutical industry, pharmacy.

SUBSTANCE: invention relates to preparing agent used in prophylaxis or relief of syndrome of the multiply risk factors. The agent used for prophylaxis or relief of syndrome of the multiple risk factors comprises at least one component taken in the definite amount and chosen from the group consisting of licorice hydrophobic extract, yellow radix extract (turmeric), clove extract and cinnamon extract. The above describes agent promotes to effective prophylaxis and relief of syndrome of multiple risk factors.

EFFECT: valuable medicinal properties of composition.

9 cl, 18 tbl, 35 ex

FIELD: medicine.

SUBSTANCE: method involves exposing instable angina pectoris patient blood samples to THz-band radiation. The radiation used for treating blood sample at molecular radiation and absorption spectrum nitrogen oxide frequency 240 GHz, power density of 1 mW/cm2 during 15 min.

EFFECT: enhanced effectiveness of treatment.

3 tbl

FIELD: pharmaceutical industry.

SUBSTANCE: invention relates to pharmaceutical kit to produce injection depo-preparation of active arylheterocyclic substance such as ziprazidone and method for production thereof. Claimed kit contains arylheterocyclic substance (ziprazidone) and liquid viscosity-providing carrier. When ziprazidone is non- solubilized said liquid carrier additionally contains solubilizer such as cyclodextrin. Pharmaceutical kit is used in treatment of schizophrenia. Injection ziprazidone depo-preparation provides delivery of active ingredient for long period of time in concentrations effective for schizophrenia treatment.

EFFECT: improved preparation for schizophrenia treatment.

15 cl, 8 tbl, 7 ex

FIELD: medicine.

SUBSTANCE: invention relates to ophthalmologic agent composition containing therapeutically active component, namely 5-bromo-6-(2-imidazolin-2-yl-amino)-quinoxaline, solubility-increasing components except for cyclodextrins, and chloroxy derivatives, preferably effective as conserving agents. Chloroxy derivatives are preferable for conserving of therapeutically active components. Solubility-increasing components includes carboxymethyl cellulose.

EFFECT: improves composition for ophthalmology.

6 cl, 7 tbl, 1 dwg, 3 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to anhydrous, antifungal, lubricating gel compositions comprising polyhydric alcohol, gelatinizing agent and an antifungal azole compound, and to a method for treatment of a patient with fungal infections comprising administration of indicated composition in a patient. Compositions shows the excellent warming and lubricating effect after its applying on skin and mucosal tissues and provides the effective treatment of fungal infections.

EFFECT: improved and valuable properties of compositions.

21 cl, 2 tbl, 11 dwg, 9 ex

FIELD: pharmaceutical agents.

SUBSTANCE: invention relates to solid pharmaceutical formulations for peroral administration useful in treatment of mild and moderately severe dementia such as Alzheimer's disease. Claimed formulation contains Rivastigmin or pharmaceutically acceptable salts thereof. Formulation represent gelatin capsule filled with pellet mixture or mixture of magnesium stearate with nonpareils, or matrix tablet.

EFFECT: preparation with controlled prolonged Rivastigmin release and improved tolerance.

3 cl, 5 ex, 15 tbl

FIELD: medicine.

SUBSTANCE: composition comprises gel-forming matrix having one or more active ingredients with prolonged release time of one or more active substances under gastrointestinal tract fluids action. Hydroxypropylmethyl cellulose of high or moderate viscosity or hydroxyethyl cellulose of high or moderate viscosity are available in the composition in 1:0.85-1:1.2 proportion, respectively. The composition optionally comprises also hydroxypropylmethyl cellulose of low viscosity with hydroxypropylmethyl cellulose of low viscosity to one of high or moderate viscosity proportion being equal to 1:0.01-1.0.2, respectively. The composition essentially does not depend on ionic force of dissolving medium habitual for gastrointestinal tract fluids as norm even if the composition is not enclosed into coating shell.

EFFECT: enhanced effectiveness of treatment.

12 cl, 4 tbl

FIELD: medicine.

SUBSTANCE: the present innovation deals with stable peroral solid composition of ramosetron or its pharmaceutically acceptable salt. The composition includes one or several components chosen out of the groups including aliphatic carboxylic acid or its ester, hydroxycarboxylic acid or its ester, acidic amino acid, enolic acid, aromatic carboxylic compound or its ester and high-molecular substance that contains carboxylic group. Such an innovation refers to the method for stabilizing ramosetron composition. The suggested innovation provides stability of ramosetron composition under conditions of increased temperature and humidity, especially at low content of active component.

EFFECT: higher efficiency of application.

14 cl, 10 ex, 6 tbl

FIELD: medicine, pharmacy.

SUBSTANCE: invention proposes a hydrophilic pharmaceutical composition with hypoglycemic effect comprising nateglinide crystals of B-type as an active component. The composition has edge angle to water surface 111 degrees or less. This edge angle is created by addition at least one hydrophilic substance to the composition chosen from groups comprising of hydrophilic polymers, surfactants, sugars and sugar-alcohols. Invention provides easy method for preparing the composition, its high solubility and rather rapid release of nateglinide.

EFFECT: improved and valuable properties of pharmaceutical composition.

13 cl, 8 dwg, 4 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: claimed viscoelastic based on 1.5-2.5 % methylcellulose contains additionally 0.0125-0.025 % dipivephrin hydrochloride solution and 0.0005-0.01 % of benzalconium chloride as stabilizer.

EFFECT: viscoelastic for prevention of eye tissues during intraocular interferences.

2 ex

FIELD: pharmaceutical industry.

SUBSTANCE: invention provides pharmaceutical composition useful as anticonvulsive drug to prevent and treat epileptic attacks. Drug is prepared in the form of oxcarbazepine-containing suspension, which, after shake, shows viscosity between 5 and 52 vPa-s. In its preferred embodiment, thixotropic oral suspension contains 5 g/ml oxcarbazepine. In another embodiment, oxcarbazepine suspension includes mixture of carboxymethylcellulose and microcrystalline cellulose in amount between 1.25 and 1.95 g/ml based on total volume of composition. In a still other embodiment, suspension contains oxcarbazepine and less than 0.5 g/ml hydroxyethylcellulose.

EFFECT: avoided lumping during storage period while preserving satisfactory flow characteristics, stability, and good tolerance at oral administration.

13 cl, 3 ex

FIELD: medicine.

SUBSTANCE: the suggested peroral preparation of controlled release contains 2-amino-3-cyano-5-(2-fluorophenyl)-4-methylpyrrole as an active ingredient. T is applied for treating pollakiuria and incontinence of urine. Application of the suggested preparation provides better quality of life in a patient who should follow certain schedule and scheme of therapy without any excessive increase in the level of medicinal preparation in blood plasma due to controlling the rate for preparation's release in vivo and, also, due to decreased frequency in the intake of the suggested medicinal preparation.

EFFECT: higher efficiency of therapy.

16 cl, 4 dwg, 10 ex

FIELD: pharmaceutical industry.

SUBSTANCE: invention relates to a method for preparing arbutin from medicinal vegetable raw. Method for preparing arbutin involves preliminary two-fold extraction of wild strawberry leaves (Fragaria vesca L.) with 70% ethyl alcohol in water bath under the definite conditions and filtration. Then an aqueous residue obtained after evaporation is held under the definite conditions and formed precipitate of resinous substances and chlorophyll is filtered off. Filtrate (aqueous residue) is treated once with chloroform and then with ethyl acetate in water bath to remove ethyl acetate, cooled and treated three times with butanol, and arbutin is eluted from column with hot water. Arbutin-containing fractions are combined, evaporated and cooled. Proposed method provides effective enhancing the yield of the end product.

EFFECT: improved preparing method.

Up!